Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.69 |
| ▸ | CA2 | P00918 | 1/20 | 0.69 |
| ▸ | MMP1 | P03956 | 1/20 | 0.69 |
| ▸ | MMP2 | P08253 | 1/20 | 0.69 |
| ▸ | MMP9 | P14780 | 1/20 | 0.69 |
| ▸ | MMP8 | P22894 | 1/20 | 0.69 |
| ▸ | MMP13 | P45452 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | F2 | P00734 | 1/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.58 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.58 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30339289 | 1.00 | CA1 (0.69) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL11514727 | 0.98 | CA1 (0.67) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL11514732 | 0.98 | CA1 (0.67) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL11514739 | 0.98 | CA1 (0.67) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL17978584 | 0.82 | CA1 (0.53) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL13026218 | 0.82 | CA1 (0.65) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL9375398 | 0.82 | CA1 (0.59) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL648427 | 0.81 | CA1 (0.69) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL30732635 | 0.81 | CA1 (0.69) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL5810580 | 0.81 | CA1 (0.69) | CA1CA2MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119233829-A | Pharmaceutical composition for preventing, inhibiting or treating symptoms associated with pseudoallergy | 学校法人高崎健康福祉大学 | 2024-12-31 | — | — | CN | claimed |
| CN-118176003-A | Medicaments comprising P2X4 receptor antagonists for the prevention or treatment of nociceptive pain and/or visceral pain | 日本化学药品株式会社 | 2024-06-11 | — | — | CN | claimed |
| CN-118019551-A | Preventive or therapeutic agent for respiratory diseases | 日本化学药品株式会社 | 2024-05-10 | — | — | CN | claimed |
| CN-115942938-A | Medicine for preventing or treating irritable bowel syndrome or inflammatory bowel disease | 比萨大学 | 2023-04-07 | — | — | CN | claimed |
| CN-113072576-B | Chiral sildenafil, synthetic method and application | 四川大学 | 2022-04-26 | — | — | CN | claimed |
| CN-113072576-A | Chiral sildenafil, synthetic method and application | 四川大学 | 2021-07-06 | — | — | CN | claimed |
| EP-4293024-B1 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC (JP) | 2026-04-08 | — | — | EP | disclosed |
| EP-4706774-A2 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | Astellas Pharma Inc. (JP) | 2026-03-11 | — | — | EP | disclosed |
| EP-4188379-B1 | POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR TREATING OR PREVENTING INFLUENZA | MERCK SHARP & DOHME LLC (US) | 2026-02-25 | — | — | EP | disclosed |
| EP-4688785-A1 | 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-D] PYRROLO [3, 2-B] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | Beone Medicines I GmbH (CH) | 2026-02-11 | — | — | EP | disclosed |
| US-20250360143-A1 | COMPOSITIONS AND METHODS FOR PHARMACOLOGIC TREATMENT OF STROKE AND MYOCARDIAL ISCHEMIA REPERFUSION INJURY | UNIV CONNECTICUT (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250340561-A1 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC (JP) | 2025-11-06 | — | — | US | disclosed |
| US-12384794-B2 | Quinazoline compound for inducing degradation of G12D mutant KRAS protein | ASTELLAS PHARMA INC. (JP) | 2025-08-12 | — | — | US | disclosed |
| EP-1175406-A1 | IMIDAZOLINE DERIVATIVES AS ALPHA-1A ADRENOCEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000066563-A1 | IMIDAZOLINE DERIVATIVES AS ALPHA-1A ADRENOCEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2000-11-09 | — | — | WO | disclosed |
| EP-0023141-B1 | HERBICIDAL SULFONAMIDES, PREPARATION AND USE THEREOF, COMPOSITIONS CONTAINING THEM, INTERMEDIATES THEREFOR AND PREPARATION OF SUCH INTERMEDIATES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-04-11 | — | — | EP | disclosed |
| US-4417917-A | BENZENE DISULFONIC ACID DERIVATIVES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-11-29 | — | — | US | disclosed |
| EP-0070041-A2 | Substituted benzenesulfonyl isocyanates and isothiocyanates and processes for their preparation | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-01-19 | — | — | EP | disclosed |
| US-4310346-A | HERBICIDES AND PLANT GROWTH REGULATORS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-01-12 | — | — | US | disclosed |
| EP-0023141-A2 | Herbicidal sulfonamides, preparation and use thereof, compositions containing them, intermediates therefor and preparation of such intermediates | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384794-B2 | Quinazoline compound for inducing degradation of G12D mutant KRAS protein | KRAS, NRAS, HRAS | CA1 2560/4885CA2 971/4885MMP1 2685/4885 |
| US-20250360143-A1 | COMPOSITIONS AND METHODS FOR PHARMACOLOGIC TREATMENT OF STROKE AND MYOCARDIAL ISCHEMIA REPERFUSION INJURY | PLAT, SERPINE1, SERPINC1 | CA1 419/4885CA2 1428/4885MMP1 59/4885 |
| US-20250340561-A1 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | KRAS, NRAS, HRAS | CA1 2560/4885CA2 971/4885MMP1 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.